Effect of gender on anti-inflammatory and analgesic actions of two kappa-opioids.
The higher incidence of inflammatory and painful disorders in women and recent reports that have emphasized the importance of gender in nociceptive sensitivity and responsiveness to analgesics prompted us to investigate gender as a factor in the variability in response to opioids. We studied the anti-inflammatory and antinociceptive effects of two kappa-opioid agonists in adjuvant-induced arthritis, one that acts both peripherally and centrally (PNU50488H; 20 mg/kg/day), the other which is peripherally selective (asimadoline; 5 mg/kg/day). Both drugs had equally powerful anti-inflammatory effects in both male and female rats (reducing measures by 60-80%). In contrast, there were gender-based heterogeneities in their analgesic actions, contingent on the method of stimulation (mechanical or thermal); males were insensitive to the analgesic effects of asimadoline with thermal but not mechanical nociceptive stimuli. We also sought evidence for gender influences on the joint content of Substance P (SP), a peptide suggested to have a role in producing inflammation and found that levels were higher in the untreated arthritic females, although there were no gender differences in disease sensitivity or nociception in arthritic animals receiving no drugs. Paradoxically, both drugs elevated SP concentrations in the joints, perhaps as a consequence of an action of kappa-opioids to suppress SP release from peripheral nerves, but the gender differences remained. Further experiments are required to determine exact mechanisms responsible for the gender distinction in analgesic response to kappa-opioids that may involve differential activation of primary afferents.
Binder
W
W
School of Physiology and Pharmacology, University of New South Wales, Sydney, New South Wales, Australia.
Carmody
J
J
Walker
J
J
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000627:therapeutic use*; D000081:Acetamides / Q000627:therapeutic use*; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000818:Animals; D001168:Arthritis / Q000139:chemically induced / Q000188:drug therapy; D001169:Arthritis, Experimental / Q000188:drug therapy*; D005260:Female; D006358:Hot Temperature / Q000009:adverse effects; D008297:Male; D009294:Narcotics / Q000494:pharmacology; D010147:Pain Measurement; D010812:Physical Stimulation / Q000009:adverse effects; D011759:Pyrrolidines / Q000627:therapeutic use*; D051381:Rats; D012727:Sex Characteristics; D013373:Substance P / Q000032:analysis; D013997:Time Factors
D000081:Acetamides; D018712:Analgesics, Non-Narcotic; D000701:Analgesics, Opioid; D009294:Narcotics; D011759:Pyrrolidines; D013373:Substance P; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; C092095:asimadoline